BACKGROUND: Irreversible hemorrhagic shock is characterized by hyporesponsiveness to vasopressor and fluid therapy. Little is known, however, about the mechanisms that contribute to this phenomenon. Previous studies have shown that decreased intestinal perfusion in hemorrhagic shock leads to proteolytically mediated increases in gut permeability, with subsequent egress of vasoactive substances systemically. Maintenance of blood pressure is achieved in part by α 1 receptor modulation, which may be affected by vasoactive factors; we thus hypothesized that decreases in hemodynamic stability and vasopressor response in shock can be prevented by enteral protease inhibition.
O ne of the most challenging problems in the care of patients suffering from circulatory shock is vasopressor resistance, which is characterized by hyporesponsiveness to the infusion of vasoactive drugs required to maintain adequate hemodynamics. The mortality of patients in shock requiring vasopressors is high (>50%) and hypotension characterizes the majority of deaths despite vasopressor support. [1] [2] [3] Although the cause of hypotension that typically accompanies and characterizes circulatory shock can be attributed to vasodilation generated by the strong inflammatory response occurring in shock, no consensus exists as to the mechanisms for vasopressor hyporeactivity. Several hypotheses have been postulated to account for vasopressor resistance. For instance, it is known that systemic vasopressin levels are reduced in shock 4 and that nitric oxide production may be increased and contributes to vasodilation and cardiac dysfunction. 5 However, clinical trials have proposed therapies interfering with these pathways without success in reducing mortality to vasopressor resistance-induced refractory shock. 6, 7 One potential mechanism contributing to hyporesponsiveness to vasopressor administration in hemorrhagic shock (HS) may be altered function of the vascular α 1 adrenergic receptor, a G q -coupled receptor which is a fundamental controller of vascular tone and determinant of systemic vascular resistance. Activation of α 1 increases intracellular calcium and subsequent smooth muscle contraction resulting in vasoconstriction of the vasculature. Although the α 1 adrenergic receptor is also found in the heart, α 1 appears to be almost exclusively involved in the maintenance of vascular tone. 8, 9 Systemic vascular resistance and thus blood pressure, when exogenously supported in the critical care setting, are with the exception of vasopressin, controlled by agents that act on the α 1 adrenergic receptor (phenylephrine, epinephrine, norepinephrine, dopamine). Therefore, decreased responsiveness to this receptor has important implications for available treatment options and outcome.
It has been previously shown that HS may reduce the surface density of important transmembrane receptors, such as the insulin receptor, 10 thus reducing the response to insulin (insulin resistance) in shock. We hypothesize that decreased transmembrane receptor density in shock may result, either directly or indirectly, from uncontrolled proteolytic activity, possibly by digestive pancreatic enzymes from the small intestine. 11 Integrity of the intestinal mucous layer is compromised in circulatory shock, [12] [13] [14] and a consequence of the breakdown of this barrier may be leakage of digestive enzymes and inflammatory products from the intestinal lumen into the bloodstream. 15 Once in the systemic circulation, these mediators may lead to remote organ failure and mortality (autodigestion).
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The objective of this study was to investigate a new hypothesis for vasopressor resistance in shock, by analyzing alterations in α 1 adrenergic receptor expression in a rat model of HS. We also tested a therapeutic intervention aimed at maintaining vasopressor responsiveness in HS, by the administration of tranexamic acid (TXA) in the intestinal lumen. Used intravenously (i.v.) to decrease bleeding predominantly due to its actions as a plasminogen inhibitor, 16 TXA also can function as a trypsin inhibitor and has been shown to improve outcomes in shock when given enterally, 15 in part by protecting the gut mucosal barrier from proteolytic degradation.
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MATERIALS AND METHODS
Experimental Protocol
All animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee at the University of California, San Diego and conform to the Guide for the Care and Use of Laboratory Animals, 8th edition, by the National Institutes of Health (2011). Twenty-four nonfasted male Wistar rats (300-450 g; Harlan Laboratories, Inc., Indianapolis, IN) were randomly assigned to either Control (no shock) (n = 6), HS (n = 6), HS with enteral TXA treatment (HS + TXA) (n = 6), or HS with enteral Golytely (HS + Vehicle) as an HS control (n = 6). All rats were anesthetized (xylazine, 4 mg/kg; ketamine, 75 mg/kg intramuscularly) with supplemental anesthesia administered i.v. as needed (xylazine, 4 mg/kg; ketamine, 7.5 mg/kg i.v.). The right femoral vein and artery were cannulated for blood withdrawal and i.v. supplemental anesthesia and continuous monitoring of arterial pressure, respectively. Body temperature was maintained at 37°C via water-heated support and heat blanket.
Control animals were monitored for 4 hours under anesthesia without other interventions. HS and HS + TXA animals were allowed 5 minutes for hemodynamic stabilization after induction of anesthesia and vascular line placement. All animals were heparinized (1 unit heparin/cc total blood volume, estimated at 6% body weight, i.v.) to allow for blood withdrawal. Hemorrhage was induced by blood withdrawal through the femoral vein (0.5 mL/min) to a target mean arterial blood pressure (MABP) of 35 mm Hg. MABP was maintained between 30 mm Hg and 40 mm Hg for 2 hours, after which time the withdrawn blood was returned to the animals (0.5 mL/min). Maintenance of MABP during the ischemic period was accomplished by the removal or return of small aliquots of blood as necessary to ensure maintenance of the targeted pressure. The shed blood was maintained at room temperature (22°C) during hypovolemia, and warmed to 37°C before return to the animals. Animals were monitored for an additional 2 hours upon completion of blood return.
To test for vascular responsiveness, the selective α 1 adrenergic agonist phenylephrine (2 μg/kg) was administered as i.v. bolus (0.1 mL) once before hemorrhage to obtain baseline response and again serially at 30 minutes, 90 minutes, and 120 minutes after the start of reperfusion. Total deflection of MABP from baseline (ΔMABP), that is, difference between maximum value of MABP after challenge and value before challenge, as well as duration of response (DOR) (time to return to within 3% of baseline) were measured as indices of vascular response to phenylephrine. In addition, % changes in the area under the curve (ΔAUC) from baseline were calculated for all animals and all groups as another method for understanding and interpreting the data.
In HS + TXA animals, TXA (127 mM TXA, Cyclokapron, Pfizer) was administered at 1 hour into the hypovolemic period into the lumen of the small intestine via sequential injections (BD Sub-Q 26G 5/8 PrecisionGlide Needle, Becton Dickinson & Co.) spaced approximately 5 cm apart for an average of eight injections longitudinally along its length. GoLytely (0.14 g/mL, 0.9% sterile water) was used as carrier solution. A total fluid volume of 15 mL was injected into the lumen of the small intestine. An additional 2 mL of TXA in vehicle was injected into the cecum. The dosage of the TXA was based on previously determined effective concentrations. 15 A second group of animals (HS + Vehicle) undergoing HS was instrumented as above and enteral injections of carrier solution only (GoLytely) were performed as an additional HS control. Hemodynamics from this group were indistinguishable from those of the HS group, and subsequent analyses were carried out on the HS animals ( Fig. 1) . HS, HS + TXA, and HS + Vehicle groups were subjected to phenylephrine challenge (2 μg/kg) as described above once before hemorrhage and at 30 minutes, 90 minutes, and 120 minutes after the start of the reperfusion period.
After a 2-hour observation period after return of shed blood (reperfusion), animals were euthanized with B-Euthanasia (120 mg/kg). Death was confirmed by loss of signal on blood pressure monitor followed by bilateral thoracotomy.
Tissue Collection
Renal arteries were harvested after laparotomy, gently rinsed to remove residual blood, and homogenized in lysis buffer (ThermoScientific). Homogenates were treated with the addition of a protease inhibitor cocktail (1:25, Roche) for Western blot analysis. Arterial homogenates were stored at −80°C for later use. Right femoral arteries were gently excised, washed four times in 10% formalin for 15 minutes each, and placed directly into 10% formalin, and stored at room temperature for immunohistochemical (IHC) analysis.
Western Blot Detection of Arterial α 1 Adrenergic Receptor
Renal artery homogenate samples from each animal (60 μL per sample; 0.5 μg/μL) were separated by Sodium dodecyle sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For Western blotting, proteins were transferred to a 0.45-μm pore size nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA; 162-0097). After blockade with 5% nonfat dry milk in buffer (Tris-Buffered Saline and Tween 20), primary antibodies against α 1D adrenergic receptor (α 1 R) (H-142, 1:300, sc-10721; Santa Cruz Biotechnology, Santa Cruz, CA) were applied. β-actin (C4, 1:100, sc-47778; Santa Cruz Biotechnology) was used as loading control. Corresponding secondary antibodies were applied at 1:5,000 dilution. Antibodies were diluted in TrisBuffered Saline and Tween 20. Supersignal West Pico Chemiluminescent substrate (ThermoFisher Scientific, Waltham, MA; 34096) was used for imaging. Molecular weights were estimated by use of an electrophoresis marker (Sigma Aldrich, C1992). Gels were digitized and bands were analyzed by densitometry in ImageJ, and results are reported as ratios of α 1 R/β-actin.
IHC Detection of Arterial α 1 Adrenergic Receptor
Femoral arteries were resected, formalin fixed, and mounted longitudinally for sectioning. Thirty μm sections were made along the length of the artery and placed in 10% formalin overnight. Sections were rinsed in distilled water to remove residual formalin. Endogenous peroxidase activity was removed with Bloxall (SP-6000; Vector Laboratories, Burlingame, CA). 2.5% normal horse serum (S-2012; Vector Laboratories) was then used as a blocking reagent followed by primary antibody incubation (ICC) with α 1D antibody (1:200, sc-10721, Santa Cruz Biotechnology, Santa Cruz, CA) for 90 minutes. Sections were incubated for 30 minutes in ImmPRESS anti-rabbit Ig (MP-7401; Vector Laboratories) and ImmPACT DAB (SK-4105; Vector Laboratories) was used for staining. Sections were mounted using Vectamount (H-5000; Vector Laboratories). Bright-field imaging was carried out at 10Â objective magnification. Images were digitized to 8-bit format and measurements were taken of smooth muscle regions in each section (six measurements/image, 10 images/animal). All analyses were performed on ImageJ. Precautions were taken to assure that all IHC steps were carried out under standard conditions to allow quantitative comparison with digital image analysis.
Immunocytochemistry of Smooth Muscle Cells After Rat Plasma ICC
Blood samples from Control (n = 6), HS (n = 6), HS + TXA (n = 6), and HS + Vehicle (n = 6) rats were drawn and blood was centrifuged at 600g for 10 minutes to achieve plasma separation. Human carotid smooth muscle cells (SMC) (HCtASMC; Cell Applications, San Diego, CA) were cultured in growth medium (311D-250; Cell Applications) at 37°C in an atmosphere of 5% CO 2 and allowed to reach approximately 100% confluence before being exposed to either starvation medium (310-500: Cell Applications), or plasma from Control, HS, HS + TXA, or HS + Vehicle animals. SMCs were incubated in the presence of plasma variant or starvation medium for 3 hours at 37°C. Cells were starved in serum free media for 12 hours before experimentation, and plasma samples were diluted in a 1:5 ratio in starvation medium immediately before ICC. Added plasma was normalized to volume rather than protein content. Cells were stained as described above for rat femoral artery sections. Images were acquired at 10Â objective magnification, digitized to 8-bit format, and measurements were taken as the average intensity for individual cells. All analyses were performed on ImageJ. Precautions were taken to assure that all ICC steps were carried out under standard conditions to allow quantitative comparison with digital image analysis.
Statistical Analysis
Data are presented as mean ± standard deviation (SD) unless otherwise noted. One-way analysis of variance was used where appropriate to evaluate the differences between groups with a post hoc Tukey correction. All analyses were performed using Graphpad (Graphpad Software Inc., La Jolla, CA). Avalue of p less than 0.05 was considered statistically significant for all tests. Sample-size calculations were made based on a preselected α = 0.05, 1-β = 0.8, with an expected difference in the primary outcome of interest (MAP) of 30 mm Hg (SD = 10) as being clinically important, based on preliminary studies.
RESULTS
Blood Pressure Response to Enteral TXA Treatment
All groups subjected to HS were maintained at similar systemic blood pressures during hypovolemia. After return of the shed blood, pressure was transiently restored, before dropping significantly in the HS and HS + Vehicle groups (Fig. 1) . The animal group treated enterally with TXA (HS + TXA) displayed significantly higher MABP after reperfusion compared with both shock groups.
Systemic Vasopressor Response
Vasopressor responsiveness to phenylephrine challenge in vivo during HS was assessed by ΔMABP and DOR at baseline, and 30 minutes, 90 minutes, and 120 minutes after the start of reperfusion (Fig. 2 ). There were no significant differences between groups for either ΔMABP or DOR at baseline. At 30 minutes after reperfusion, there was a significant decrease in DOR for the HS + Vehicle group ( p = 0.001) and ΔMABP for both HS and HS + Vehicle groups compared to baseline ( p = 0.005, p < 0.0001, respectively) ( Figs. 3 and 4) . This decrement in function in the untreated HS groups continued for the duration of the experiment in both HS and HS + Vehicle groups at 90 minutes in ΔMABP ( p = 0.001, p = 0.003, respectively) and DOR ( p = 0.03, p = 0.02, respectively), and at 120 minutes in ΔMABP ( p = 0.02, p = 0.002, respectively), and DOR ( p = 0.002, p = 0.006, respectively). At no time point during the study did ΔMABP or DOR in the HS + TXA group differ significantly from baseline. Changes in the ΔAUC from baseline (100%) were measured between the HS + Vehicle (26%, p = 0.05) and HS groups (37%, p = 0.064) versus HS + TXA (71% of baseline response) at 90 minutes with significant differences between HS + Vehicle (23%, p = 0.006) and HS (26%, p = 0.002) versus HS + TXA (71%) at 120 minutes.
α 1 Adrenergic Receptor Levels
The α 1 adrenergic receptor was examined by Western blot to determine whether there were changes in α 1 receptor density in shock and whether these levels were preserved after treatment with enteral TXA. α 1 receptor density was markedly decreased ( p = 0.001) by HS as measured by Western blot (Fig. 5A ) but maintained near Control levels by enteral treatment with TXA. Measurements of α 1 receptor density were confirmed using IHC combined with digital image analysis (Fig. 5C ), where receptor levels as detected by immunolabeling were also significantly decreased in HS compared with Control ( p = 0.004). Enteral 
Human Carotid SMC α 1 Adrenergic Receptor Levels
SMCs were examined for α 1 using ICC (Fig. 6) . α 1 receptor density was significantly decreased in HS and HS + Vehicle compared with Control groups ( p = 0.001, p = 0.018, respectively), whereas ICC with plasma from the HS + TXA group resulted in levels similar to Control. α 1 receptor levels from the HS + Vehicle and HS groups did not differ significantly from each other.
DISCUSSION
Fulminate decompensated HS (class IV), 19 characterized by limited responsiveness to fluid bolus and vasopressor therapy, carries a poor prognosis, in part because no effective interventions exist. Lack of responsiveness to vasopressors and failure to maintain vascular tone, commonly described in septic shock, are not well documented for HS, and although several hypotheses have been proposed, there currently exists no consensus as to mechanism. 20 To study this problem, we examined the role of the α 1 adrenergic receptor in experimental HS. The α 1 receptor is the archetypical adrenergic receptor most responsible for maintaining systemic vascular tone (vasoconstriction), and we hypothesized that failure of this receptor, either through reduced density or function, results in decreased vascular tone and subsequent hemodynamic collapse in HS. 8 Furthermore, we hypothesized that enteral treatment with TXA, a mild trypsin inhibitor, 21 would lead to improved hemodynamics in HS, in part by maintaining α 1 receptor activity by prevention of proteolytically mediated processes. The mechanisms of action by which enteral TXA is effective in experimental HS appears unrelated to TXA's well-known clinical role as an antifibrinolytic. Although IV TXA has some efficacy in HS, 16 this has not been consistently reported. 22 Other protease inhibitors with differing effects on the coagulation system have also been found to be effective when given enterally to treat experimental shock, 23, 24 and the limited patient information on the subject appears to support the hypothesis that the protease inhibitors must be given enterally to display marked clinical improvement. 25 This study confirms previous reports that enteral inhibition with TXA leads to improved hemodynamics in experimental HS. 15 Using phenylephrine as a probe for α 1 adrenergic receptor responsiveness, we report here that systemic sensitivity to this receptor decreases in experimental HS with concomitant decrements in systemic pressure maintenance. The decrease in hemodynamic response is manifest as measured by attenuated changes in mean systemic blood pressure (ΔMABP) and in the DOR to the pressor agent phenylephrine, as well as by changes in the total hemodynamic effectiveness of phenylephrine (ΔAUC). This reduction in hemodynamic responsiveness begins early in the reperfusion period and continues unabated through the end of the experiment. Western blot analysis and IHC confirm decreased α 1 adrenergic receptor density in HS; the decrement in density appears to be a mechanism by which α 1 receptormediated hyporesponsiveness is mediated. This result is consistent with reports from other investigators on adrenergic function in shock, which appears to be predominantly related to changes in receptor density rather than function. 26 The mechanisms by which vascular α 1 adrenergic receptor density is modulated in shock are unknown, but results from our study demonstrate that circulating factors in the blood may be operant. These circulating mediators may include digestive pancreatic proteases 15 and products of proteolysis that either directly, 27 or indirectly through vasoactive degradation products 14 affect receptor function, and thus vascular responsiveness. Supporting this hypothesis are our current findings that enteral TXA restores receptor levels to baseline concentrations with commensurate improvements in hemodynamics in experimental HS by protecting the ischemic small bowel from proteolytic degradation; 11, 12, 15 this protection is not seen with i.v. protease inhibitor treatment. 28 There are several limitations to this study. Among these is the lack of a detailed described mechanism by which enteral TXA inhibition in the bowel restores α 1 receptor function systemically. Previous studies have demonstrated increased survival after experimental shock with enteral protease inhibition, 15 but not with i.v. protease inhibition. 28, 29 The reasons for this are twofold: first, the high concentrations of proteolytic enzymes in the bowel (millimolar range) can only be overcome by high concentrations of inhibitor in the bowel lumen, which is not feasible in the systemic circulation. Second, and more importantly, by limiting proteolytic degradation of the bowel mucosa and resulting permeability changes, 13, 17, 18, 30 enteral protease inhibition prevents the systemic egress of nonprotease gut mediators that might otherwise affect α 1 receptor function and result in subsequent hypotension. Further studies are necessary to identify the mediators and mechanisms responsible for this phenomenon. Likewise, although changes in α 1 receptor responsiveness appear to be secondary to changes in density as shown by Western blot and IHC analysis, the possibility of abnormal α 1 receptor binding or malfunction in HS cannot be excluded. Finally, it is acknowledged that other receptors, both adrenergic (e.g., β 1 , β 2 ) and otherwise (e.g., vasopressin), are also operant and may be affected in HS; further studies are necessary to clarify the roles of these receptors in this condition and the possible effect of enteral TXA in modulating them.
In conclusion, this study proposes a possible mechanism for vasopressor resistance-induced refractory shock by demonstrating that HS decreases α 1 adrenergic receptor responsiveness and density. Decrements in α 1 adrenergic receptor activity and concentrations are mitigated by enteral treatment with TXA, with resultant improved hemodynamics and vascular responsiveness. Restoration of α 1 receptor density and functionality may be a key mechanism by which enteral TXA improves systemic blood pressure and survival in experimental HS. 
